Complaint Handling and Distribution Record Procedures under SOR/2026-110 in Canada

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

From 14 December 2026, manufacturers, importers and distributors must each establish, implement and maintain documented procedures covering: distribution records (new section 52(3)), complaint handling and the related procedures (replaced section 58), handling, storage, delivery, installation, servicing and corrective action for Class II–IV devices (new section 58.1), incident reporting procedures (new sections 59(3)(4)), and information provision procedures (new section 61.2(4)).

  • The obligation falls on the three parties, each separately: no party can rely on another party’s procedures.
  • New section 58.1 lists six activities for Class II–IV devices: handling, storage, delivery, installation, servicing, and corrective action, each “as applicable”.
  • The incident reporting procedures are tiered by class: section 59(3) covers Class I, including foreign incidents; section 59(4) covers Class II–IV.
  • Section 61.2(4) addresses information provision procedures for MDL holders and importers of Class II–IV devices.
  • According to the regulatory impact analysis statement of SOR/2026-110, the procedures are “often missing, have gaps in documentation and implementation, and may be out of date” despite earlier declarations in licence applications.
  • The compliance deadline for all five groups of provisions is 2026-12-14.

2. Legal basis

All obligations in this article come from SOR/2026-110, the Regulations Amending the Medical Devices Regulations (establishment licences), read together with the existing provisions of the Medical Devices Regulations. The table below lists each item relied on.

Regulation / documentProvisionDateSource
SOR/2026-110, item 4New section 52(3): manufacturers, importers and distributors must each establish, implement and maintain documented procedures for distribution recordsIn force 2026-12-14Canada Gazette, Part II
SOR/2026-110, item 5Replaces section 58: the three parties must each establish, implement and maintain documented procedures that enable them to carry out (the activities listed in the section)SameSame
SOR/2026-110, item 6New section 58.1: procedures for the handling, storage, delivery, installation and servicing of Class II–IV devices, and for corrective action taken on a deviceSameSame
SOR/2026-110, item 7New sections 59(3)(4): preliminary and final report procedures for Class I and for Class II–IVSameSame
SOR/2026-110, item 8New section 61.2(4): information provision procedures for MDL holders and importers of Class II–IV devicesSameSame
Medical Devices RegulationsSection 57 (complaint handling related)SOR/98-282Justice Laws

3. Expert insights

The 2026 amendment converts what used to be expectations around licence declarations into express, enforceable procedure obligations. Four points determine how a company should read the new text.

Insight 1: the duty holder is “each of the three parties”, not “any one of them”.

The amended provisions consistently use the formulation “the manufacturer, importer and distributor … must each establish, implement and maintain documented procedures”. None of the three parties can rely on another party’s procedures to satisfy its own duty. A foreign manufacturer cannot point to its importer’s distribution record procedures, and an importer cannot point to the manufacturer’s complaint handling procedures.

Insight 2: new section 58.1 is a complete list of six activities.

New section 58.1 covers, for Class II–IV devices, handling, storage, delivery, installation and servicing, as well as corrective action taken on a device — six activities in total, each qualified by “as applicable”. Companies should confirm applicability activity by activity, and in particular should not drop corrective action from the list simply because it is the last item.

Insight 3: the procedure obligations are tiered by device class.

Section 59(3) targets manufacturers and importers of Class I devices and covers preliminary and final reports under sections 59(1) and (1.1) — that is, including foreign incidents. Section 59(4) targets manufacturers and importers of Class II–IV devices and covers reports under section 59(1). The Class I procedure scope is therefore broader, which is the reverse of how the licence regimes themselves are tiered. Companies holding both Class I and Class II–IV portfolios should keep the two sets of procedures distinguishable so that reviewers can see which tier each document belongs to.

Insight 4: a procedure is no longer compliant by declaration alone.

According to the regulatory impact analysis statement of SOR/2026-110, these documented procedure requirements are “not new and do not impose additional burdens on stakeholders”, but the same statement records inspection findings that, despite declarations made in earlier applications, these procedures are “often missing, have gaps in documentation and implementation, and may be out of date”. This signals that the focus of inspections will shift from whether a declaration exists to whether the procedures actually run. Operating records, not just documents, are what will be examined.

4. Practical recommendations

  • Compare existing procedures item by item against the five groups of provisions: 52(3), 58, 58.1, 59(3)(4), and 61.2(4).
  • Establish procedures separately for the three parties — manufacturer, importer and distributor — rather than sharing one document.
  • Confirm the applicability of each of the six activities in section 58.1, and in particular do not omit corrective action.
  • Establish incident reporting procedures separately for Class I and for Class II–IV.
  • Leave operating records for every procedure, not only the document itself — the inspection focus is on operation.
  • Schedule the remediation work backwards from 2026-12-14, so that the five groups of procedures are complete and running before the provisions come into force.

5. Verification checklist

  • □ Procedures for the five groups of provisions have been compared item by item and gaps closed
  • □ Procedures have been established separately by the manufacturer, the importer and the distributor
  • □ The applicability of the six activities in section 58.1 has been confirmed item by item
  • □ Incident reporting procedures have been established separately for Class I and Class II–IV
  • □ Operating records exist for every procedure (not only the documents)
  • □ Remediation completion has been scheduled before 2026-12-14

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail